Home Healthcare IT Active Implantable Medical Devices Market Size, Share and Forecast to 2031

Active Implantable Medical Devices Market

Active Implantable Medical Devices Market Size, Share & Trends Analysis Report By Product (Implantable Cardioverter Defibrillators, Transvenous Implantable Cardioverter Defibrillators, Subcutaneous Implantable Cardioverter Defibrillators, Implantable Cardiac Pacemakers, Ventricular Assist Devices, Implantable Heart Monitors/Insertable Loop Recorders, Neurostimulators, Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, Gastric Electrical Stimulators, Implantable Hearing Devices, Active Hearing Implants, Passive Hearing Implants), By End User (Hospitals, Ambulatory Surgery Center, Specialty Clinics) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI4DR
Study Period 2019-2031 CAGR 7.2%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD 22.65 Billion
Forecast Year 2031 Forecast Year Market Size USD 42.35 Billion
Largest Market Europe Fastest Growing Market North America
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global active implantable medical devices market size was valued at USD 22.65 billion in 2022. It is projected to reach USD 42.35 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2023–2031).

Rising elderly population, growing prevelance of cardiovascular diseaes and increasing global burden on ecnomies are propelling the market. As per WHO, around 17.9 million people die every year from CVDs, which accounts for 31% of all deaths globally. In addition, increasing cases of neurological disorders such as Parkinson’s disease, epilepsy, and dystopia is observed to be high in emerging economies such as India. Neurostimulation is an effective treatment for these neurological diseases. As per Global Burden of Disease report, rate of cases per 100,000 people has increased in Parkinson's by 15.7 percent, Alzheimer's 2.4 percent, and brain and nervous system cancers 8.9 percent.

New products are being launched to meet the demand of consumers by market players. For instance, in 2016 , Medtronic launched  first leadless pacemaker Micra TPS. Introduction of wireless technology and mobile connectivity has enhanced the effectiveness of these devices. In the same year, Boston Scientific Corporation launched the Precision Montage MRI Spinal Cord Stimulator (SCS) System, which gives access to full body magnetic resonance imaging (MRI) in a 1.5 Tesla environment.For instance, in 2017, Cochlear collaborated with Apple to provide cochlear implants with iPhone connectivity. 

Regional Analysis

Geographically, the global active implantable medical devices market is segmented into four regions: North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).

North America is likely to dominate the market due to increasing geriatric population, rising prevalence of cardiovascular and neurological diseases, accessibility to advanced technologies, and increasing healthcare expenditure in the region. As per Disease Control and Prevention (CDC), 2017, around 2.7 to 6.1 million people in were suffering from atrial fibrillation, the most common type of heart arrhythmia in the U.S.

Europe is likely to emerge as the second largest market globally. This can be attributed to increasing incidences of chronic disease and reimbursement policy for implantation of pacemakers to reduce the financial burden. According to world’s export data, in 2017, European countries exported highest number of heart pacemakers during with the worth around USD 5 billion or 91.3% of the global total.

Asia pacific market is expected to witness significant growth on account of high prevalance of chronic diseases, aging population, healthcare reforms for infrastructural development, growing and less stringent regulations for new product development. As per the study conducted by The Global Burden of Disease, CVD death rate was 272 per 1,00000 individuals in India higher than the global average of 235.

LAMEA is expected to witness steady growth. Latin America is most affected by heart disease and it has put an economic burden of around USD 30.9 billion in 2015 and approximately 89.6 million people are diagnosed with the condition in the region.

Report Scope

Report Metric Details
By Product
  1. Implantable Cardioverter Defibrillators
  2. Transvenous Implantable Cardioverter Defibrillators
    1. Biventricular Implantable Cardioverter Defibrillators
    2. Dual-Chamber Implantable Cardioverter Defibrillators
    3. Single-Chamber Implantable Cardioverter Defibrillators
  3. Subcutaneous Implantable Cardioverter Defibrillators
  4. Implantable Cardiac Pacemakers
  5. Ventricular Assist Devices
  6. Implantable Heart Monitors/Insertable Loop Recorders
  7. Neurostimulators
  8. Spinal Cord Stimulators
  9. Deep Brain Stimulators
  10. Sacral Nerve Stimulators
  11. Vagus Nerve Stimulators
  12. Gastric Electrical Stimulators
  13. Implantable Hearing Devices
  14. Active Hearing Implants
  15. Passive Hearing Implants
By End User
  1. Hospitals
  2. Ambulatory Surgery Center
  3. Specialty Clinics
Company Profiles Medtronic PLC Abbott Laboratories Boston Scientific Corporation Livanova PLC Nurotron Biotechnology Co. Ltd. Biotronik Se & Co., Kg William Demant Holding A/S Cochlear Limited Sonova Holding AG
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

Segmented by Product and End-User

By product, the market is segmented into implantable cardioverter defibrillators, implantable cardiac pacemakers, implantable heart monitors/insertable loop recorders, ventricular assist devices, neurostimulators and implantable hearing devices. The implantable cardioverter defibrillators segment is expected to grow at the fastest CAGR. The growth can be attributed to increasing incidence of cardiovascular diseases, technologically advanced devices and increasing demand for these devices in developing countries. Implantable cardioverter defibrillators are further segmented into single chamber, dual chamber, and biventricular pacemaker devices.

Based on end user, the market is segmented into hospitals, ambulatory surgery centers and specialty clinics. Rising investments and improving healthcare infrastructure is contributing in the hospital sector to emerge as the most prominent end user in the years to come.

Market Size By Product

Top Key Players

Medtronic PLC Abbott Laboratories Boston Scientific Corporation Livanova PLC Nurotron Biotechnology Co. Ltd. Biotronik Se & Co., Kg William Demant Holding A/S Cochlear Limited Sonova Holding AG Others

Frequently Asked Questions (FAQs)

What is the market value of Active Implantable Medical Devices Market by 2031?
The market value of Active Implantable Medical Devices Market by 2031 is USD 42.35 billion.
The CAGR value during the forecast period is 7.2% .
North America region has the highest growth rate in the Market.
The key players in the global Market include Medtronic PLC , Abbott Laboratories , Boston Scientific Corporation , Livanova PLC , Nurotron Biotechnology Co. Ltd. , Biotronik Se & Co., Kg , William Demant Holding A/S , Cochlear Limited , Sonova Holding AG.
The global Market is segmented by product type, end user, and regions channel.

We are featured on :